Newbury Pharmaceuticals Full Year 2024 Earnings: kr0.72 loss per share (vs kr0.99 loss in FY 2023)

Newbury Pharmaceuticals (STO:NEWBRY) Full Year 2024 Results

Key Financial Results

• Revenue: kr36.8m (up 259% from FY 2023).
• Net loss: kr15.4m (loss narrowed by 21% from FY 2023).
• kr0.72 loss per share (improved from kr0.99 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Newbury Pharmaceuticals Earnings Insights

In the last 12 months, the only revenue segment was Pharmaceuticals contributing kr36.8m. Notably, cost of sales worth kr20.8m amounted to 56% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to kr28.8m (92% of total expenses). Explore how NEWBRY's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 2 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are down 3.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Newbury Pharmaceuticals (1 is significant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.